TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomas

Abstract Background Transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFF2) is a transmembrane in the tomoregulin family. Little research has been performed to determine whether TMEFF2 methylation prognostic marker adult diffuse gliomas. Methods In this study, we investigated expression surgical glioma tissue samples. addition, conducted bisulfite amplicon sequencing (BSAS) methylation-specific PCR (MSP) evaluate glioblastoma (GBM) cells. Subsequently, biological function of GBM Moreover, explored significance gliomas by analysing cohort dataset from TCGA. Results Immunohistochemistry analysis 75 paired tumour peritumoural tissues demonstrated that expressed lower levels than (P < 0.001). promoter were increased cells compared SVG p12 Inhibition reduced its LN229 T98G 0.05). Knockdown significantly promoted proliferation U87MG primary negatively associated IDH1, ATRX TP53 mutations, subtype harbouring combined IDH1/ATRX/TP53 mutations was low levels. Survival confirmed are good prognosis patients. Conclusions Our results suggest DNA might be progression could serve as valuable for